A Single-Center, Prospective Clinical Cohort Study on Perioperative Management, Exposure, Multiorgan Outcomes, and Functional Recovery in Liver Transplantation

November 12, 2026 updated by: Yi Duan, Beijing Tsinghua Chang Gung Hospital

The objective of this observational study (a single-center, prospective, consecutively enrolled clinical cohort) is to establish a cohort of adult liver transplant recipients to correlate, within the same population, the recipients' preoperative status with graft condition, perioperative medical and therapeutic exposures, and dynamic physiological changes, as well as multiorgan outcomes and functional recovery; to identify factors associated with organ injury and difficulties in recovery; and to provide a basis for subsequent clinical validation and intervention studies. The study population consists of adult recipients aged ≥18 years who are scheduled to undergo their first single-liver transplant at this center; continuous enrollment is planned for 5 years, with a target of 450 participants, each followed for 12 months. Recipients undergoing repeat liver transplantation or combined organ transplantation will be included only in a separate expanded registry and analysis.

The primary research questions it aims to address are:

What is the incidence rate and 95% confidence interval of the patient-level composite outcome-defined as all-cause mortality or at least one of the predefined major organ complications (early graft dysfunction/graft failure, new-onset or worsening moderate-to-severe acute kidney injury, new-onset delirium or confirmed acute neurological event, major cardiovascular event, or major pulmonary complication)-within 30 days after the start of the transplant procedure? After accounting for preoperative disease severity, organ function, and graft condition, how are perioperative clinical exposures and physiological changes-such as circulatory, respiratory, temperature, and EEG parameters-associated with multiorgan outcomes and functional recovery at 12 months? Can prespecified dynamic physiological data provide additional information regarding risk or recovery beyond routine clinical data?

This study has no control group; no treatment will be assigned; routine monitoring, testing, or rehabilitation arrangements will not be altered; and no additional blood draws or tissue samples will be collected. Participants will:

Undergo preoperative baseline data collection and assessments of cognition, frailty, functional status, and quality of recovery; some participants will complete the sleep and mood extension modules (PSQI, HADS).

During the perioperative period, participants will allow the research team to record clinically generated treatment exposures and multimodal monitoring data, including circulatory, respiratory, temperature, and EEG parameters.

Participants will complete relevant follow-up visits and functional assessments on postoperative days 7, 30, and 90, as well as at 6 and 12 months, including the QoR-15, DAH-30/90, and assessments of cognition, frailty, functional status, and quality of life.

Follow-up should preferably be conducted in conjunction with routine follow-up visits; when necessary, survival, hospitalization, and living conditions may be verified via approved telephone contact. Additional clinical testing using residual serum and tissue samples is optional; refusal to provide these samples will not affect enrollment in the study.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

450

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 102218
        • Recruiting
        • Beijing Tsinghua Changgung Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

This is a single-center study, and the study population is sourced from Beijing Tsinghua Changgung Hospital. Adult recipients (aged ≥18 years) scheduled to undergo primary single liver transplantation at this center are consecutively screened during waitlist registration, inpatient preoperative evaluation, or pre-transplant preparation. With an estimated 100 adult liver transplant surgeries performed annually at this center, approximately 450 recipients are planned to be enrolled consecutively over a 5-year period.

Description

Inclusion Criteria:

  1. Age ≥ 18 years.
  2. Scheduled to undergo primary single liver transplantation at this center.
  3. The participant or legally authorized representative has completed the ethically approved informed consent process.

(Note: Patients undergoing emergency transplantation, preoperative hepatic encephalopathy, intensive care, mechanical ventilation, and renal replacement therapy are eligible. Donor type and disease severity will be retained as stratification information.)

Exclusion Criteria:

  1. Age < 18 years.
  2. History of previous liver transplantation.
  3. This surgery is a combined organ transplantation.
  4. Refusal to participate.
  5. Unable to complete valid authorization under the informed consent procedure approved for this study.

(Note: Patients undergoing re-transplantation and combined organ transplantation may enter a separate extended registry within the same ethical framework, but will not be mixed into the primary analysis cohort of primary single liver transplantation and its sample size denominator.)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of participants with all-cause mortality or at least one major organ complication within 30 days after the start of transplant surgery, assessed according to preset clinical criteria (e.g., Olthoff definition, KDIGO criteria).
Time Frame: From the start of surgery to 30 days postoperatively.
From the start of surgery to 30 days postoperatively.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 22, 2026

Primary Completion (Estimated)

October 22, 2031

Study Completion (Estimated)

October 22, 2032

Study Registration Dates

First Submitted

November 12, 2026

First Submitted That Met QC Criteria

November 12, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 12, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 27410-4-01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.